Immune Response International Licensing Small Molecule 
The Pharma Data
NOVEMBER 18, 2020
.” Ming-Tain Lai, PhD, Chief Scientific Officer at OBI Pharma stated, “In the trial, OBI-833 demonstrated a favorable safety profile and generated detectable anti-Globo H IgM/IgG responses. Title: A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients. Presenter: Ching-Liang Ho MD, et.al.
The Pharma Data
JANUARY 17, 2021
By inhibiting calcineurin, the drug blocks IL-2 expression and T-cell mediated immune responses. On December 17, 2020, Aurinia inked a collaboration and license deal with Japan’s Otsuka Pharmaceutical Co. Myelosuppression happens when radiation damages internal organs, including bone marrow.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
MAY 6, 2021
It is the decision of sovereign States to offer immunization to athletes and their delegations in accordance with their local guidance before travelling to Japan for the Tokyo Games. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. NEW YORK & MAINZ, Germany–(BUSINESS WIRE)– Pfizer Inc.
The Pharma Data
SEPTEMBER 9, 2020
Today’s decision is a further illustration of how collaboration and solidarity can help address a global health crisis as an international community,” said Ugur Sahin, M.D., During preclinical and clinical studies, BNT162b1 and BNT162b2 emerged as strong candidates based on assessments of safety and immune response.
The Pharma Data
AUGUST 3, 2021
The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. Loxo Oncology at Lilly and Kumquat Biosciences Inc.
The Pharma Data
SEPTEMBER 8, 2020
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules.
The Pharma Data
SEPTEMBER 8, 2020
Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. the United States. the United States.
Expert insights. Personalized for you.
52 
Let's personalize your content